ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of 31.21 billion. The enterprise value is 31.53 billion.
| Market Cap | 31.21B |
| Enterprise Value | 31.53B |
Important Dates
The next estimated earnings date is Wednesday, April 23, 2025.
| Earnings Date | Apr 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.02% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 145.64M |
Valuation Ratios
The trailing PE ratio is 24.99.
| PE Ratio | 24.99 |
| Forward PE | n/a |
| PS Ratio | 6.33 |
| PB Ratio | 5.94 |
| P/TBV Ratio | 15.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.91, with an EV/FCF ratio of 22.65.
| EV / Earnings | 25.25 |
| EV / Sales | 6.40 |
| EV / EBITDA | 17.91 |
| EV / EBIT | 20.16 |
| EV / FCF | 22.65 |
Financial Position
The company has a current ratio of 3.33, with a Debt / Equity ratio of 0.16.
| Current Ratio | 3.33 |
| Quick Ratio | 1.74 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 0.48 |
| Debt / FCF | 0.60 |
| Interest Coverage | 65.73 |
Financial Efficiency
Return on equity (ROE) is 25.65% and return on invested capital (ROIC) is 16.30%.
| Return on Equity (ROE) | 25.65% |
| Return on Assets (ROA) | 13.89% |
| Return on Invested Capital (ROIC) | 16.30% |
| Return on Capital Employed (ROCE) | 24.81% |
| Revenue Per Employee | 493,665 |
| Profits Per Employee | 125,121 |
| Employee Count | 9,980 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 1.91 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +57.40% in the last 52 weeks. The beta is 0.76, so ResMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | +57.40% |
| 50-Day Moving Average | 24.24 |
| 200-Day Moving Average | 20.58 |
| Relative Strength Index (RSI) | 29.37 |
| Average Volume (20 Days) | 157 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.11 |
Income Statement
In the last 12 months, ResMed had revenue of 4.93 billion and earned 1.25 billion in profits. Earnings per share was 8.47.
| Revenue | 4.93B |
| Gross Profit | 2.91B |
| Operating Income | 1.56B |
| Pretax Income | 1.53B |
| Net Income | 1.25B |
| EBITDA | 1.71B |
| EBIT | 1.56B |
| Earnings Per Share (EPS) | 8.47 |
Balance Sheet
The company has 521.94 million in cash and 839.74 million in debt, giving a net cash position of -317.79 million.
| Cash & Cash Equivalents | 521.94M |
| Total Debt | 839.74M |
| Net Cash | -317.79M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.25B |
| Book Value Per Share | 35.77 |
| Working Capital | 1.98B |
Cash Flow
In the last 12 months, operating cash flow was 1.48 billion and capital expenditures -84.56 million, giving a free cash flow of 1.39 billion.
| Operating Cash Flow | 1.48B |
| Capital Expenditures | -84.56M |
| Free Cash Flow | 1.39B |
| FCF Per Share | n/a |
Margins
Gross margin is 59.02%, with operating and profit margins of 31.67% and 25.35%.
| Gross Margin | 59.02% |
| Operating Margin | 31.67% |
| Pretax Margin | 31.16% |
| Profit Margin | 25.35% |
| EBITDA Margin | 34.75% |
| EBIT Margin | 31.67% |
| FCF Margin | 28.25% |
Dividends & Yields
ResMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 23.76% |
| Buyback Yield | 0.02% |
| Shareholder Yield | 0.02% |
| Earnings Yield | 4.00% |
| FCF Yield | 4.46% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ResMed has an Altman Z-Score of 12.76.
| Altman Z-Score | 12.76 |
| Piotroski F-Score | n/a |